Zydus Cadila gets USFDA nod to market Telmisartan tablets in US

01 Sep 2014 Evaluate

Pharma major, Zydus Cadila has received the final approval from the US drug regulator -- US Food and Drug Administration (USFDA) -- to market Telmisartan tablets of 20mg, 40mg and 80mg in the US market.

The estimated sales in 2014 for Telmisartan tablets, which fall in the anti-hypertensive segment is $233.3 million, as per IMS. The group now has 96 approvals and has so far filed 249 ANDAs since the commencement of the filing process in FY 2003-04.

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. It is the only Indian pharma company to launch its own patented NCE - Lipaglyn, the world’s first drug to be approved for the treatment of diabetic dyslipidemia.

Zydus Lifesciences Share Price

914.65 13.35 (1.48%)
31-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1719.75
Dr. Reddys Lab 1271.05
Cipla 1510.90
Zydus Lifesciences 914.65
Lupin 2112.00
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×